Genentech, Exelixis drug combo slows deadly skin cancer

Exelixis Inc. stock surged before backing off Monday after partner Genentech Inc. said a late-stage study that combined Exelixis' cobimetinib and Genentech's Zelboraf indicated that advanced skin cancer patients could live more than three months longer...